fda 503b bulks list removal

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List — Photo by Castorly Stock on Pexels

Cut Costs By Excluding Semaglutide Bulk

Hospitals can lower drug spend by moving away from bulk-compounded semaglutide and using commercially packaged alternatives or negotiated contracts. A single FDA decision could add $1.2 million in procurement costs for a large tertiary hospital next year. Medical Disclaimer: This article is for informational purposes only and does not